Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients
Conclusion: In lieu of the human pharmacokinetic data, although the administration of diastereomeric darolutamide was justified, it is proposed to delineate the clinical pharmacokinetics of S,Rdarolutamide and S,S-darolutamide relative to darolutamide in future clinical pharmacology studies.
Source: Drug Metabolism Letters - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Liver | Oral Cancer | Prostate Cancer | Study | Urology & Nephrology